Suppr超能文献

很少有药物呈现出双翻转药代动力学,并且这些药物主要与生物药剂学分类系统(BDDCS)的3类和4类相关。

Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS.

作者信息

Garrison Kimberly L, Sahin Selma, Benet Leslie Z

机构信息

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California.

Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.

出版信息

J Pharm Sci. 2015 Sep;104(9):3229-35. doi: 10.1002/jps.24505. Epub 2015 May 25.

Abstract

This study was conducted to determine the number of drugs exhibiting flip-flop pharmacokinetics following oral (p.o.) dosing from immediate-release dosage forms and if they exhibit a common characteristic that may be predicted based on BDDCS classification. The literature was searched for drugs displaying flip-flop kinetics (i.e., absorption half-life larger than elimination half-life) in mammals in PubMed, via internet search engines and reviewing drug pharmacokinetic data. Twenty two drugs were identified as displaying flip-flop kinetics in humans (13 drugs), rat (nine drugs), monkey (three drugs), horse (two drugs), and/or rabbit (two drugs). Nineteen of the 22 drugs exhibiting flip-flop kinetics were BDDCS Classes 3 and 4. One of the three exceptions, meclofenamic acid (Class 2), was identified in the horse; however, it would not exhibit flip-flop kinetics in humans where the p.o. dosing terminal half-life is 1.4 h. The second, carvedilol, can be explained based on solubility issues, but the third sapropterin dihydrochloride (nominally Class 1) requires further consideration. The few drugs displaying p.o. flip-flop kinetics in humans are predominantly BDDCS Classes 3 and 4. New molecular entities predicted to be BDDCS Classes 3 and 4 could be liable to exhibit flip-flop kinetics when the elimination half life is short and should be suspected to be substrates for intestinal transporters.

摘要

本研究旨在确定口服速释剂型给药后呈现出翻转药代动力学的药物数量,以及它们是否具有基于生物药剂学分类系统(BDDCS)分类可预测的共同特征。通过在PubMed中检索、利用互联网搜索引擎并查阅药物药代动力学数据,在文献中查找在哺乳动物中呈现翻转动力学(即吸收半衰期大于消除半衰期)的药物。已确定有22种药物在人类(13种药物)、大鼠(9种药物)、猴子(3种药物)、马(2种药物)和/或兔子(2种药物)中呈现翻转动力学。呈现翻转动力学的22种药物中有19种属于BDDCS 3类和4类。三个例外之一的甲氯芬那酸(2类)是在马中发现的;然而,在人类中口服给药时其末端半衰期为1.4小时,不会呈现翻转动力学。第二个药物卡维地洛可基于溶解度问题来解释,但第三个药物盐酸沙丙蝶呤(名义上为1类)需要进一步研究。在人类中呈现口服翻转动力学的少数药物主要属于BDDCS 3类和4类。预测为BDDCS 3类和4类的新分子实体在消除半衰期较短时可能易于呈现翻转动力学,并且应怀疑是肠道转运体的底物。

相似文献

1
Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS.
J Pharm Sci. 2015 Sep;104(9):3229-35. doi: 10.1002/jps.24505. Epub 2015 May 25.
3
BDDCS class prediction for new molecular entities.
Mol Pharm. 2012 Mar 5;9(3):570-80. doi: 10.1021/mp2004302. Epub 2012 Feb 7.
6
BDDCS applied to over 900 drugs.
AAPS J. 2011 Dec;13(4):519-47. doi: 10.1208/s12248-011-9290-9. Epub 2011 Aug 5.
7
Intestinal drug transporters: an overview.
Adv Drug Deliv Rev. 2013 Oct;65(10):1340-56. doi: 10.1016/j.addr.2012.09.042. Epub 2012 Oct 4.
8
Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System.
Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):162-7. doi: 10.1111/j.1742-7843.2009.00498.x. Epub 2009 Dec 7.

引用本文的文献

1
Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9.
J Med Chem. 2025 May 8;68(9):9537-9554. doi: 10.1021/acs.jmedchem.5c00252. Epub 2025 Apr 29.
2
Determination of QLNC-3A6 in canine plasma by UHPLC-MS/MS and its application in pharmacokinetic studies.
Vet Q. 2024 Dec;44(1):1-11. doi: 10.1080/01652176.2024.2407174. Epub 2024 Oct 10.
3
Commentary: Pharmacokinetic Theory Must Consider Published Experimental Data.
Drug Metab Dispos. 2024 Aug 14;52(9):932-938. doi: 10.1124/dmd.124.001735.
4
Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies.
Cancer Chemother Pharmacol. 2024 Sep;94(3):361-372. doi: 10.1007/s00280-024-04688-y. Epub 2024 Jun 15.
7
A Systematic Review on the Clinical Pharmacokinetics of Cephalexin in Healthy and Diseased Populations.
Antibiotics (Basel). 2023 Sep 3;12(9):1402. doi: 10.3390/antibiotics12091402.
10
Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice.
Cancer Chemother Pharmacol. 2022 Jun;89(6):795-807. doi: 10.1007/s00280-022-04436-0. Epub 2022 May 4.

本文引用的文献

4
The UCSF-FDA TransPortal: a public drug transporter database.
Clin Pharmacol Ther. 2012 Nov;92(5):545-6. doi: 10.1038/clpt.2012.44.
5
Intestinal drug transporters: an overview.
Adv Drug Deliv Rev. 2013 Oct;65(10):1340-56. doi: 10.1016/j.addr.2012.09.042. Epub 2012 Oct 4.
7
BDDCS applied to over 900 drugs.
AAPS J. 2011 Dec;13(4):519-47. doi: 10.1208/s12248-011-9290-9. Epub 2011 Aug 5.
9
The role of transporters in the pharmacokinetics of orally administered drugs.
Pharm Res. 2009 Sep;26(9):2039-54. doi: 10.1007/s11095-009-9924-0. Epub 2009 Jun 30.
10
The use of drug metabolism for prediction of intestinal permeability (dagger).
Mol Pharm. 2009 Jan-Feb;6(1):74-81. doi: 10.1021/mp8001864.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验